FDA Advisory Committee Strongly Endorses Use of Trasylol® in CABG Surgery Patients
Bayer was glad to participate in today’s advisory committee meeting held by the Cardiovascular and Renal Drugs Division of the U.S. Food and Drug Administration (FDA). This session provided an open forum in which to discuss the complex scientific issues surrounding the risk/benefit profile of Trasylol® (aprotinin injection) in detail.
